Calls are ongoing for Northern Ireland to follow Scotland’s lead in which Pharmaceutical Price Regulation Scheme (PPRS) payments are going into a new medicines fund that covers treatments for rare and end-of-life conditions, the Belfast Telegraph reports.
Implemented in 2014, the PPRS enables the pharmaceutical sector to make payments to the government depending on the growth of branded medicines.
In Scotland, the payments are being invested in a new medicines fund that covers treatments for rare and end-of-life conditions, with there being 40 or so cancer drugs available in the rest of the UK, yet with strictly limited usage in Northern Ireland.
To read the full story, click here.
